“NorthStar has quickly achieved several key milestones in advancing our strategically planned RadioGenix System roll-out,” said George P. Messina, Chairman and CEO of NorthStar. “First, the FDA approval of our Beloit manufacturing facility enables us to scale up production and expand capacity to meet anticipated customer demand. The approval came well in advance of the anticipated FDA action date. Second, we are also very pleased to announce that the commercial launch of the RadioGenix System has commenced, with the first contract signed and the first installation scheduled at a customer site. This important event marks another milestone in NorthStar’s commitment to provide the United States healthcare system with a reliable, domestic non-uranium based Mo-99 supply for production of the important medical diagnostic imaging radioisotope, technetium-99m. We anticipate shipping additional RadioGenix Systems as potential customers receive licensing amendments for their sites, and look forward to sharing our progress.” Read the full story here.
- Wisconsin ‘Creative Destruction Lab’ to be featured at 2020 Early Stage SymposiumOctober 1, 2020
- InsideWis: Wisconsin’s growing reputation as COVID hotspot not good for business – or anyoneSeptember 30, 2020
- Want to compete for COVID innovation grants? Learn more Thursday during Tech Council webinarSeptember 29, 2020
- How to apply for state COVID innovation grants: Learn more at Oct. 1 Tech Council webinarSeptember 29, 2020
- Cap Times Idea Fest: Public and private efforts boost COVID-19 testing but community should still ‘double down’ on preventionSeptember 29, 2020